-
Something wrong with this record ?
The effect of novel [3-fluoro-(2-phosphonoethoxy)propyl]purines on the inhibition of Plasmodium falciparum, Plasmodium vivax and human hypoxanthine-guanine-(xanthine) phosphoribosyltransferases
O. Baszczyňski, D. Hocková, Z. Janeba, A. Holý, P. Jansa, M. Dračínský, DT. Keough, LW. Guddat,
Language English Country France
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Antiprotozoal Agents chemical synthesis chemistry pharmacology MeSH
- Enzyme Inhibitors chemical synthesis chemistry pharmacology MeSH
- Humans MeSH
- Models, Molecular MeSH
- Molecular Structure MeSH
- Parasitic Sensitivity Tests MeSH
- Pentosyltransferases antagonists & inhibitors metabolism MeSH
- Plasmodium falciparum drug effects MeSH
- Plasmodium vivax drug effects MeSH
- Purines chemical synthesis chemistry pharmacology MeSH
- Dose-Response Relationship, Drug MeSH
- Structure-Activity Relationship MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Protozoan parasites from the Plasmodiidae family are the causative agents of malaria. Inhibition of hypoxanthine-guanine-(xanthine) phosphoribosyltransferase (HG(X)PRT) has been suggested as a target for development of new anti-malarial therapeutics. Acyclic nucleoside phosphonates (ANPs) are potent and selective inhibitors of plasmodial HG(X)PRTs. A new series of ANPs, based on the chemical structure and inhibitory activity of three ANPs, 2-(phosphonoethoxy)ethyl with either guanine or hypoxanthine as the base (PEEG and PEEHx) and 3-hydroxy-2-(phosphonomethoxy)propyl with guanine as the base (HPMPG), were prepared. These compounds are stereoisomers of 3-fluoro-(2-phosphonoethoxy)propyl (FPEPs) and 3-fluoro-(2-phosphonomethoxy)propyl (FPMPs) analogues. Both the (R)- and (S)-isomers of these fluorinated derivatives have higher Ki values (by 10- to 1000-fold) for human HGPRT and Plasmodium falciparum HGXPRT than the non-fluorinated ANPs. Possible explanations for these changes in affinity are proposed based on docking studies using the known crystal structures of human HGPRT in complex with PEEG.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14064101
- 003
- CZ-PrNML
- 005
- 20140708122831.0
- 007
- ta
- 008
- 140704s2013 fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejmech.2013.06.032 $2 doi
- 035 __
- $a (PubMed)23850568
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Baszczyňski, Ondřej $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Flemingovo nám. 2, CZ-166 10 Prague 6, Czech Republic.
- 245 14
- $a The effect of novel [3-fluoro-(2-phosphonoethoxy)propyl]purines on the inhibition of Plasmodium falciparum, Plasmodium vivax and human hypoxanthine-guanine-(xanthine) phosphoribosyltransferases / $c O. Baszczyňski, D. Hocková, Z. Janeba, A. Holý, P. Jansa, M. Dračínský, DT. Keough, LW. Guddat,
- 520 9_
- $a Protozoan parasites from the Plasmodiidae family are the causative agents of malaria. Inhibition of hypoxanthine-guanine-(xanthine) phosphoribosyltransferase (HG(X)PRT) has been suggested as a target for development of new anti-malarial therapeutics. Acyclic nucleoside phosphonates (ANPs) are potent and selective inhibitors of plasmodial HG(X)PRTs. A new series of ANPs, based on the chemical structure and inhibitory activity of three ANPs, 2-(phosphonoethoxy)ethyl with either guanine or hypoxanthine as the base (PEEG and PEEHx) and 3-hydroxy-2-(phosphonomethoxy)propyl with guanine as the base (HPMPG), were prepared. These compounds are stereoisomers of 3-fluoro-(2-phosphonoethoxy)propyl (FPEPs) and 3-fluoro-(2-phosphonomethoxy)propyl (FPMPs) analogues. Both the (R)- and (S)-isomers of these fluorinated derivatives have higher Ki values (by 10- to 1000-fold) for human HGPRT and Plasmodium falciparum HGXPRT than the non-fluorinated ANPs. Possible explanations for these changes in affinity are proposed based on docking studies using the known crystal structures of human HGPRT in complex with PEEG.
- 650 _2
- $a antiprotozoální látky $x chemická syntéza $x chemie $x farmakologie $7 D000981
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a inhibitory enzymů $x chemická syntéza $x chemie $x farmakologie $7 D004791
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a molekulární modely $7 D008958
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a parazitické testy citlivosti $7 D021261
- 650 _2
- $a pentosyltransferasy $x antagonisté a inhibitory $x metabolismus $7 D010430
- 650 _2
- $a Plasmodium falciparum $x účinky léků $7 D010963
- 650 _2
- $a Plasmodium vivax $x účinky léků $7 D010966
- 650 _2
- $a puriny $x chemická syntéza $x chemie $x farmakologie $7 D011687
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Hocková, Dana
- 700 1_
- $a Janeba, Zlatko
- 700 1_
- $a Holý, Antonín
- 700 1_
- $a Jansa, Petr
- 700 1_
- $a Dračínský, Martin
- 700 1_
- $a Keough, Dianne T
- 700 1_
- $a Guddat, Luke W
- 773 0_
- $w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 67, č. - (2013), s. 81-9
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23850568 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20140704 $b ABA008
- 991 __
- $a 20140708123120 $b ABA008
- 999 __
- $a ok $b bmc $g 1031585 $s 862833
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 67 $c - $d 81-9 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
- LZP __
- $a Pubmed-20140704